{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T11:46:45Z","timestamp":1773661605771,"version":"3.50.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"1-3","license":[{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biophysical Chemistry"],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1016\/j.bpc.2010.08.001","type":"journal-article","created":{"date-parts":[[2010,8,8]],"date-time":"2010-08-08T08:46:22Z","timestamp":1281257182000},"page":"65-73","source":"Crossref","is-referenced-by-count":14,"title":["pH-dependent interaction of psychotropic drug with glycerophospholipid monolayers studied by the Langmuir technique"],"prefix":"10.1016","volume":"152","author":[{"given":"Signe","family":"Steinkopf","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aida","family":"Simeunovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helene J.","family":"Bustad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thi Ha","family":"Ngo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hege","family":"Sveaass","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anja U.","family":"Gjerde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holm","family":"Holmsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bpc.2010.08.001_bb0005","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0022-3565(25)10792-1","article-title":"The behavioural pharmacology of olanzapine, a novel \u201catypical\u201d antipsychotic agent","volume":"262","author":"Moore","year":"1992","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bpc.2010.08.001_bb0010","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0920-9964(98)00146-7","article-title":"Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and \u03b11-adrenergic receptors in vitro","volume":"37","author":"Bymaster","year":"1999","journal-title":"Scizophr. Res."},{"key":"10.1016\/j.bpc.2010.08.001_bb0015","first-page":"87","article-title":"Neuroendocrine evidence for antagonism of serotonin and dopamine receptors by olanzapine (LY170053), an antipsychotic drug candidate","volume":"77","author":"Fuller","year":"1992","journal-title":"Res. Commun. Chem. Pathol. Pharmacol."},{"key":"10.1016\/j.bpc.2010.08.001_bb0020","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0893-133X(94)00129-N","article-title":"Radioreceptor binding profile of the atypical antipsychotic olanzapine","volume":"14","author":"Bymaster","year":"1996","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bpc.2010.08.001_bb0025","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1192\/S0007125000293653","article-title":"Olanzapine: a basic science update","volume":"37","author":"Bymaster","year":"1999","journal-title":"Br. J. Psychiatry Suppl."},{"key":"10.1016\/j.bpc.2010.08.001_bb0030","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S0022-3565(25)38596-4","article-title":"Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors","volume":"268","author":"Roth","year":"1994","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bpc.2010.08.001_bb0035","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0014-2999(01)01399-1","article-title":"Potent antagonism of 5-HT3 and 5-HT6 receptors by olanzapine","volume":"430","author":"Bymaster","year":"2001","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bpc.2010.08.001_bb0040","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0014-2999(00)00037-6","article-title":"Decreased binding affinity of olanzapine and clozapine for human muscarine receptors in intact clonal cells in physiological medium","volume":"390","author":"Bymaster","year":"2000","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bpc.2010.08.001_bb0045","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2165\/00003495-199753020-00007","article-title":"A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses","volume":"53","author":"Fulton","year":"1997","journal-title":"Drugs"},{"key":"10.1016\/j.bpc.2010.08.001_bb0050","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1176\/ajp.154.4.457","article-title":"Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial","volume":"154","author":"Tollefson","year":"1997","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.bpc.2010.08.001_bb0055","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1176\/ajp.156.5.702","article-title":"Olanzapine HGEH studt group, olanzapine versus placebo in the treatment of acute mania","volume":"156","author":"Tohen","year":"1999","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.bpc.2010.08.001_bb0060","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0893-133X(95)00069-P","article-title":"Olanzapine HGAD study group, olanzapine versus placebo and haloperidol: acute phase results of North American double-blind olanzapine trial","volume":"14","author":"Beasley","year":"1996","journal-title":"Neuropsychopharmacol."},{"key":"10.1016\/j.bpc.2010.08.001_bb0065","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1055\/s-0038-1647307","article-title":"Trifluoperazine enhances accumulation and inhibits phosphohydrolysis of phosphatidate in thrombin-stimulated platelets","volume":"64","author":"Holmsen","year":"1990","journal-title":"Thromb. Haemostasis."},{"key":"10.1016\/j.bpc.2010.08.001_bb0070","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0014-5793(90)80757-A","article-title":"Evidence that chlorpromazine and prostaglandin E1 but not neomycin interfere with the inositol phospholipid metabolism in intact human platelets","volume":"264","author":"Tysnes","year":"1990","journal-title":"FEBS let."},{"key":"10.1016\/j.bpc.2010.08.001_bb0075","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1016\/0006-2952(92)90104-Q","article-title":"Chlorpromazine increases the turnover of metabolically active phosphoinositides and elevates the steady-state level of phosphatidylinositol-4-phosphate in human platelets","volume":"44","author":"Fr\u00f8lich","year":"1992","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bpc.2010.08.001_bb0080","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0006-2952(00)00445-7","article-title":"The stimulatory effects of cationic amphiphilic drugs on human platelets treated with thrombin","volume":"60","author":"Tharmapathy","year":"2000","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bpc.2010.08.001_bb0085","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1007\/s002100000339","article-title":"Dopamine receptors in human platelets, FNaunyn-Schiedeberg's","volume":"363","author":"Ricci","year":"2001","journal-title":"Arch. Pharmacol."},{"key":"10.1016\/j.bpc.2010.08.001_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/S0031-6997(25)06931-5","article-title":"The membrane actions of anesthetics and tranquilizers","author":"Seeman","year":"1972","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.bpc.2010.08.001_bb0095","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/0006-2952(86)90269-8","article-title":"Phenothiazine drugs and metabolites: molecular conformation and dopaminergic, alpha adrenergic and muscarinic cholinergic receptor binding","volume":"35","author":"Dahl","year":"1986","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bpc.2010.08.001_bb0100","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0006-2952(01)00542-1","article-title":"Chlorpromazine-induced increase in dipalmitoylphosphatidylserine surface area in monolayers at room temperature","volume":"61","author":"Agas\u00f8ster","year":"2000","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bpc.2010.08.001_bb0105","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0301-4622(01)00152-1","article-title":"Chlorpromazine associates with phosphatidylserines to cause an increase in the lipid's own interfacial molecular area \u2014 role of the fatty acyl composition","volume":"91","author":"Agas\u00f8ster","year":"2001","journal-title":"Biophys. Chem."},{"key":"10.1016\/j.bpc.2010.08.001_bb0110","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1021\/la061628b","article-title":"Trifluoperazine causes a disturbance in glycerophospholipid monolayers containing phosphatidylserine (PS): effects of pH, acyl unsaturation, and proportion of PS","volume":"23","author":"Broniec","year":"2007","journal-title":"Langmuir"},{"key":"10.1016\/j.bpc.2010.08.001_bb0115","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0005-2736(00)00125-5","article-title":"Chlorpromazine interaction with glycerophospholipid liposomes studied by magic angle spinning solid state 13C-NMR and differential scanning calorimetry","volume":"1464","author":"Nerdal","year":"2000","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bpc.2010.08.001_bb0120","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.bbalip.2004.01.004","article-title":"Chlorpromazine interaction with phosphatidylserines: A 13C and 31P solid-state NMR study","volume":"1682","author":"Gjerde","year":"2004","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bpc.2010.08.001_bb0125","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.bpc.2005.05.002","article-title":"Importance of polyunsaturated acyl chains in chlorpromazine interaction with phosphatidylserines: A 13C and 31P solid-state NMR study","volume":"117","author":"Chen","year":"2005","journal-title":"Biophys. Chem."},{"key":"10.1016\/j.bpc.2010.08.001_bb0130","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.bpc.2005.11.007","article-title":"Existence of lipid microdomains in bilayer of dipalmitoylphosphatidylcholine (DPPC) and 1-stearoyl-2-docosahexenoylphosphatidylserine (SDPS) and their perturbation by chlorpromazine: a 13C and 31P solid-state NMR study","volume":"120","author":"Song","year":"2006","journal-title":"Biophys. Chem."},{"issue":"2","key":"10.1016\/j.bpc.2010.08.001_bb0135","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s12154-009-0018-6","article-title":"In thrombin stimulated human platelets citalopram, promethazine, risperidone, and ziprasidone, but not diazepam, may exert their pharmacological effects also through intercalation in membrane phospholipids in a receptor-independent manner","volume":"2","author":"Oruch","year":"2009","journal-title":"J. Chem. Biol."},{"key":"10.1016\/j.bpc.2010.08.001_bb0140","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1016\/j.bbamem.2008.04.007","article-title":"Psychotropic drugs interfere with the tight coupling of polyphosphoinositide cycle metabolites in human platelets: a result of receptor-independent drug intercalation in the plasma membrane?","volume":"1778","author":"Oruch","year":"2008","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bpc.2010.08.001_bb0145","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.bpc.2008.01.003","article-title":"The psychotropic drug olanzapine (Zyprexa\u00ae) increases the area of acid glycerophospholipid monolayers","volume":"134","author":"Steinkopf","year":"2008","journal-title":"Biophys. Chem."},{"key":"10.1016\/j.bpc.2010.08.001_bb0150","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.bpc.2008.01.002","article-title":"Olanzapine interaction with dipalmitoyl phosphatidylcholine (DPPC) and 1-palmitoyl-2-oleoyl phosphatidylserine (POPS) bilayer: A 13C and 31P solid-state NMR study","volume":"134","author":"Song","year":"2008","journal-title":"Biophys. Chem."},{"issue":"17","key":"10.1016\/j.bpc.2010.08.001_bb0155","doi-asserted-by":"crossref","first-page":"8804","DOI":"10.1021\/jp056678o","article-title":"Molecular dynamics simulations of neutral chlorpromazine in zwitterionic phospholipid monolayers","volume":"110","author":"Pickholz","year":"2006","journal-title":"J. Phys. Chem. B"},{"issue":"no 5279","key":"10.1016\/j.bpc.2010.08.001_bb0160","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1126\/science.273.5279.1196","article-title":"Phase and morphology changes in lipid monolayers induced by SP-B protein and its amino-terminal peptide","volume":"273","author":"Lipp","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.bpc.2010.08.001_bb0165","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1021\/bi00547a034","article-title":"Bilayers of phospatidylserine: a deuterim and phosphorus nuclear magnetic resonance study","volume":"19","author":"Browning","year":"1980","journal-title":"Biochemistry"},{"key":"10.1016\/j.bpc.2010.08.001_bb0170","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1107\/S0567740869005437","article-title":"The crystal and molecular structure of chlorpromazine","volume":"B25","author":"McDowell","year":"1969","journal-title":"Acta Cryst."},{"key":"10.1016\/j.bpc.2010.08.001_bb0175","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1021\/cg034055z","article-title":"Anhydrates and hydrates of olanzapine: crystallisation, solid-state characterization, and structural relationships","volume":"6","author":"Reutzel-Edens","year":"2003","journal-title":"Crystal Groth E. Design"},{"issue":"1-2","key":"10.1016\/j.bpc.2010.08.001_bb0180","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ijpharm.2006.07.023","article-title":"Solid state characterization of olanzapine polymorphs using vibrational spectroscopy, International","volume":"326","author":"Ayala","year":"2006","journal-title":"J. Pharmaceutics"},{"key":"10.1016\/j.bpc.2010.08.001_bb0185","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ijpharm.2005.05.035","article-title":"Thermal behaviour and stability in olanzapine, International","volume":"301","author":"Polla","year":"2005","journal-title":"J. Pharmaceutics"}],"container-title":["Biophysical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030146221000195X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030146221000195X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,23]],"date-time":"2025-02-23T23:11:23Z","timestamp":1740352283000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030146221000195X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11]]},"references-count":37,"journal-issue":{"issue":"1-3","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["S030146221000195X"],"URL":"https:\/\/doi.org\/10.1016\/j.bpc.2010.08.001","relation":{},"ISSN":["0301-4622"],"issn-type":[{"value":"0301-4622","type":"print"}],"subject":[],"published":{"date-parts":[[2010,11]]}}}